A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis

Summary

The purpose of this study is to evaluate the efficacy of guselkumab plus golimumab combination treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) to prior anti-tumor necrosis factor-alpha (anti-TNF-alpha) therapies by assessing clinical response compared with guselkumab monotherapy.

Timeline

Start

2021-10-25

Primary completion

2024-05-14

Completion

2024-08-06

Drugs

Indications